# A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

> **NCT04867980** · PHASE1 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ACP-196
- **DRUG:** Moxifloxacin 400 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04867980
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-01
- **Primary completion:** 2016-05-09
- **Final completion:** 2016-05-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04867980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04867980, "A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04867980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*